Table 5.
Proportional costs of both approaches to manage persistent febrile neutropenia in a hematological patient
| Therapy outcomea | DDAT approachb |
Standard approachc |
||||
|---|---|---|---|---|---|---|
| Proportion (%) | Cost (€)/patient | Weighted cost (€) | Proportion (%) | Cost (€)/patient | Weighted cost (€) | |
| Overall successful response | 36.5 | 8,309 | 3,033 | 33.9 | 11,692 | 3,964 |
| Successful response with EAT | 17. 2 | 10,845 | 1,911 | 33.9 | 11,692 | 3,964 |
| Successful response without EAT | 18.81 | 5,964 | 1,122 | |||
| Overall failure response | 63.5 | 13,976 | 8,875 | 66.1 | 20,915 | 13,825 |
| Failure response with EAT | 43.57 | 17,635 | 7,683 | 66.1 | 20,915 | 13,825 |
| Death | 12.9 | 10,288 | 1,327 | 9.04 | 11,726 | 1,060 |
| Breakthrough IFI | 1.17 | 17,575 | 207 | 4.84 | 22,390 | 1,084 |
| Premature discontinuation | 8.23 | 20,669 | 1,701 | 19.91 | 22,339 | 4,448 |
| Persistent fever | 21.18 | 20,963 | 4,440 | 32.33 | 22,394 | 7,240 |
| Failure response without AT | 19.98 | 5,964 | 1,191 | |||
| Total cost per patient | 11,910 | 17,789 | ||||
a
EAT, empirical antifungal therapy; IFI, invasive fungal infection. “Failure response without EAT” refers to all cases of failure response without receiving empirical antifungal therapy were due to the fever not being resolved for at least 48 h before the neutropenia resolution.
b
That is, the DDAT approach recommended by the SAEI (12).
c
That is, the standard EAT approach recommended by the IDSA (4).